- Home
- SLXN vs XXII Comparison
SLXN vs XXII Comparison
Compare SLXN & XXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLXN
- XXII
- Stock Information
- Founded
- SLXN 2008
- XXII 1998
- Country
- SLXN Israel
- XXII United States
- Employees
- SLXN N/A
- XXII N/A
- Industry
- SLXN
- XXII Medicinal Chemicals and Botanical Products
- Sector
- SLXN
- XXII Health Care
- Exchange
- SLXN NYSE
- XXII Nasdaq
- Market Cap
- SLXN 7.3M
- XXII 7.0M
- IPO Year
- SLXN N/A
- XXII N/A
- Fundamental
- Price
- SLXN $0.80
- XXII $6.45
- Analyst Decision
- SLXN Strong Buy
- XXII
- Analyst Count
- SLXN 1
- XXII 0
- Target Price
- SLXN $5.00
- XXII N/A
- AVG Volume (30 Days)
- SLXN 141.1K
- XXII 49.6K
- Earning Date
- SLXN 08-21-2025
- XXII 08-12-2025
- Dividend Yield
- SLXN N/A
- XXII N/A
- EPS Growth
- SLXN N/A
- XXII N/A
- EPS
- SLXN N/A
- XXII N/A
- Revenue
- SLXN N/A
- XXII $23,869,000.00
- Revenue This Year
- SLXN N/A
- XXII $22.41
- Revenue Next Year
- SLXN N/A
- XXII $76.35
- P/E Ratio
- SLXN N/A
- XXII N/A
- Revenue Growth
- SLXN N/A
- XXII N/A
- 52 Week Low
- SLXN $0.58
- XXII $6.28
- 52 Week High
- SLXN $41.85
- XXII $2,837.04
- Technical
- Relative Strength Index (RSI)
- SLXN N/A
- XXII 22.22
- Support Level
- SLXN N/A
- XXII $6.93
- Resistance Level
- SLXN N/A
- XXII $9.50
- Average True Range (ATR)
- SLXN 0.00
- XXII 1.57
- MACD
- SLXN 0.00
- XXII 0.03
- Stochastic Oscillator
- SLXN 0.00
- XXII 9.75
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.